biostudies-literatureUnknownMiddha PNCATS NIH HHSNICHD NIH HHSNCRR NIH HHSNHLBI NIH HHSNHGRI NIH HHSNINDS NIH HHSNCI NIH HHSNIH HHSNIGMS NIH HHSImmune checkpoint inhibitors (ICIs) are a remarkable advancement in cancer therapeutics; however, a substantial proportion of patients develop severe immune-related adverse events (irAEs). Understanding and predicting irAEs is a key to advancing precision immuno-oncology. Immune checkpoint inhibitor-mediated colitis (IMC) is a significant complication from ICI and can have life-threatening consequences. Based on clinical presentation, IMC mimics inflammatory bowel disease, however the link is poorly understood. We hypothesized that genetic susceptibility to Crohn's disease (CD) and ulcerative colitis (UC) may predispose to IMC. We developed and validated polygenic risk scores for CD (PRS_CD) and UC (PRS_UC) in cancer-free individuals and assessed the role of each of themedRxiv : the preprint server for health sciences2023.05.15.23289680https://www.ebi.ac.uk/biostudies/studies/S-EPMC10246037biostudies-literaturePolygenic risk score for ulcerative colitis predicts immune checkpoint inhibitor-mediated colitis.PMC10246037T32 CA009207UL1 TR002243UG1 CA233259P30 CA008748U01 HG004798RC2 GM092618U01 HG006378S10 OD017985R01 CA251758UL1 TR000445R01 NS032830P30 CA068485UL1 RR024975P50 GM115305U01 CA253560K24 CA169004P01 CA129243S10 RR025141R01 HD074711R01 CA227466U19 HL065962Quandt ZHuntsman SCardenas EPatel DZiv EFaleck DMFalcon CJAldrich MCThummalapalli RKachuri LMiddha PBalaratnam KBalko JMYao LBejan CAMurray MHJohnson DBLi MBetti MJZhan LJWerking KSchoenfeld AJKhan KPrincess Margaret Lung GroupLovly CMGubens MAXu YLiu GfalsePolygenic risk score for ulcerative colitis predicts immune checkpoint inhibitor-mediated colitis.Immune checkpoint inhibitors (ICIs) are a remarkable advancement in cancer therapeutics; however, a substantial proportion of patients develop severe immune-related adverse events (irAEs). Understanding and predicting irAEs is a key to advancing precision immuno-oncology. Immune checkpoint inhibitor-mediated colitis (IMC) is a significant complication from ICI and can have life-threatening consequences. Based on clinical presentation, IMC mimics inflammatory bowel disease, however the link is poorly understood. We hypothesized that genetic susceptibility to Crohn's disease (CD) and ulcerative colitis (UC) may predispose to IMC. We developed and validated polygenic risk scores for CD (PRS_CD) and UC (PRS_UC) in cancer-free individuals and assessed the role of each of the2023-01-01T00:00:00Z2023 Sep2025-04-19T05:38:35.347Z2025-04-19T05:38:35.347ZS-EPMC102460373729275110.1101/2023.05.15.23289680